Inclusion Criteria:

   - Patients must be rated 2 or more on both Q1 and Q3, but they must not meet the full
   criteria for PD as determined by the Anxiety Disorders Interview Schedule for
   DSM-IV-Lifetime Version (ADIS).

   - In addition, they must be clinically stable enough that changes in the patients'
   anxiety levels can be attributed to the breathing training rather than to other new
   treatment initiatives during the training and 1-month evaluation periods or to
   spontaneous fluctuations in anxiety levels. Thus, potential participants taking SSRIs
   or other antidepressants, or benzodiazepines have to have been on a stable dose of
   these medicines for at least the previous two months.

Exclusion Criteria:

   - Potential participants taking short-acting benzodiazepines such as alprazolam in
   excess of 2.0 mg/day or the equivalent on any day in the past month are excluded,
   because improvement might show up only in terms of reduction of medication dosage and
   not on the evaluation measures planned.